<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0DE6810-C22C-433E-9160-263AFCEF5D4D"><gtr:id>A0DE6810-C22C-433E-9160-263AFCEF5D4D</gtr:id><gtr:name>Ludger Ltd</gtr:name><gtr:address><gtr:line1>Culham Science Centre</gtr:line1><gtr:postCode>OX14 3EB</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Genetics and Molecular Medicine</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0DE6810-C22C-433E-9160-263AFCEF5D4D"><gtr:id>A0DE6810-C22C-433E-9160-263AFCEF5D4D</gtr:id><gtr:name>Ludger Ltd</gtr:name><gtr:address><gtr:line1>Culham Science Centre</gtr:line1><gtr:postCode>OX14 3EB</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/259A9C4C-8DF6-48F9-B626-B414032F4DC8"><gtr:id>259A9C4C-8DF6-48F9-B626-B414032F4DC8</gtr:id><gtr:firstName>Frank</gtr:firstName><gtr:surname>Nestle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D488F9E2-71B9-460D-A435-0951340D01E7"><gtr:id>D488F9E2-71B9-460D-A435-0951340D01E7</gtr:id><gtr:firstName>Sophia</gtr:firstName><gtr:otherNames>N.</gtr:otherNames><gtr:surname>Karagiannis</gtr:surname><gtr:orcidId>0000-0002-4100-7810</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL023091%2F1"><gtr:id>7B8B4538-26B5-4B1A-89C7-6603177B242B</gtr:id><gtr:title>Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L023091/1</gtr:grantReference><gtr:abstractText>Cancer treatments which mobilise the patient's own immune system to fight cancerous cells (immunotherapy) are proving to be an exciting new approach in the fight against cancer. Antibodies are proteins that recognise alien entities in the body and trigger their destruction by immune cells. Antibodies recognising surface proteins (antigens) on cancer cells are now generated in the laboratory, designed to specifically seek out tumours displaying these surface antigens. To work, antibodies must also bind to immune cells, which in turn target those cancer cells. Antibodies come in five types, but only one, IgG, has been used in cancer therapy. Unfortunately, IgG binds relatively poorly to immune cells and works inefficiently in tissues, where tumours grow. Another antibody type, namely IgE, known as the key component of allergies, may be better suited to cancer therapy, because of its excellent binding to immune cells and ability to activate these cells in tissues. Our earlier work on designing IgE antibodies in relation to the therapy of ovarian cancer has already elicited encouraging results that engender optimism and we plan to test this antibody in patients soon.
We are now working to apply the same principles towards the treatment of the most lethal skin cancer, malignant melanoma. Melanoma cells are subject to immune scrutiny, that is they display on their surfaces antigens, the targets for an antibody. To investigate this, we produced CSPG4 IgE, an antibody specifically recognising melanoma cancer cells. When we tested this antibody in the laboratory, it was very effective in activating immune cells to destroy cancer. We now plan to complete these studies so that this therapy may benefit patients with malignant melanoma for whom few effective therapies are available.</gtr:abstractText><gtr:technicalSummary>The clinical landscape for the lethal skin cancer, melanoma, is transformed by novel agents including an antibody targeting T-cell regulatory pathways, which, despite moderate clinical responses and high toxicities, demonstrates promise for antibody therapies. Yet, there are presently no antibodies directly targeting melanoma cells. This strategy entails an antibody targeting melanoma antigens that is engineered with Fc regions of the IgE antibody class. Attributes of IgE such as natural tissue immune activatory functions and high affinity for cognate Fc receptors on frequently tumour-resident effector cells can translate into superior protection against solid tumours compared to conventionally-used IgGs. These advantages are demonstrated by efficacy and safety in three in vivo tumour models and remarkable progress through process development of our successful first IgE antibody targeting Folate Receptor alpha-expressing cancers, now approaching first-in-man clinical trials supported by the CRUK New Agents Committee. We engineered IgE and IgG1 antibodies recognising CSPG4, a cell surface tumour antigen over-expressed by 80% of melanomas; CSPG4 participates in melanoma pathogenesis and progression through activation of key signalling pathways. CSPG4 IgE demonstrated superior efficacy in targeting melanoma and direct and cell-mediated tumour-killing activities, suggesting a multifactorial mode of action. Background IP is owned by KCL through a PCT application filed in 2011. Here, we will evaluate efficacy and safety of this agent through functional assays on patient and healthy volunteer blood and in disease-relevant models, some of which will also serve to support future evaluations in the pre-clinical development and clinical study stages. Study design is based on expertise with our lead antibody, to directly progress CSPG4 IgE to process development and clinical trials.</gtr:technicalSummary><gtr:potentialImpactText>Substantial knowledge on Th2 immunity in cancer and IgE functions in the context of cancer therapy is presently being acquired in conjunction with our parallel on-going research and development activities with our lead agent. These activities are fully supported from funds independent to this application and will contribute added-value to our existing activities. Collectively, our research and development activities and knowledge acquired as part of this proposed study towards the clinical application of the concept for a second target and in a different set of clinical indications are of paramount importance towards making this approach widely applicable for cancer therapy. 
There are several options for the future progression of the programme, especially in relation to other cancer types known to express CSPG4. This would include expansion into larger indications such as breast cancer, including breast carcinomas termed &amp;quot;triple-negative.&amp;quot; This latter programme, as part of our newly funded Breakthrough Breast Cancer Unit at King's College London/Guy's Hospital (5-year Unit headed by Prof. Andrew Tutt; co-PIs: Karagiannis, Nestle, Ng) will commence with in vitro and in vivo models of breast cancer. Application as a therapy for breast cancer and specifically for triple-negative breast carcinomas is expected to report results in parallel with data acquired as part of this proposed study and will provide added value to this study. 
This study also stands to make a substantial impact in the wider field of immune and antibody therapeutics. Our research on Th2 immunity, IgE and cancer is receiving increasing attention from the academic, medical and biotechnology communities. We have been approached by three biotechnology companies (Novartis, Biotechnol, UCB) who have shown strong interest specifically in relation to IgE immunotherapy, for example toward a collaborative effort to develop IgE antibody fragments with multiple specificities including CSPG4
If successful this proposed study will: a) point to strategies by which Th2 immune responses could be harnessed to target tumours; b) provide a new therapeutic avenue to potentially benefit the majority of the 112,000 in the UK living with malignant melanoma; c) pave the way towards the development of a new class of therapeutic antibody agents with improved immune activatory functions which could be redirected against cancers of different origins. 
If unsuccessful, this study will be informative in informing the design of novel immune activatory strategies, especially those aimed at overcoming tumour-induced immune escape mechanisms and those aimed at re-educating inflammatory cells to attack rather than promote tumour growth.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>977991</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludger Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Defining and designing altered IgE glycoforms</gtr:description><gtr:id>919F8768-5951-4D50-910D-273E8CAE89EF</gtr:id><gtr:impact>Work has begun using high-performance glycoanalytics to establish a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.</gtr:impact><gtr:partnerContribution>Ludger Ltd provide high-performance glycoanalytics to establish a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.</gtr:partnerContribution><gtr:piContribution>Our laboratory is leading novel work to examine the role of glycans for IgE activity, and to exploit this knowledge for the development of altered IgE glycoforms. Bringing together expertise in IgE pharmacology (Karagiannis), chemical inhibitors of glycan biosynthesis (Wagner) and high-performance glycoanalytics (Ludger Ltd), we will provide proof-of-concept for a cost effective, flexible, operationally simple and potentially generic method for the glycoengineering of recombinant therapeutic glycoproteins.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Radcliffe Department of Medicine Careers Day, St Anne's College, University of Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>71B04048-6B59-4825-98A2-7ECAFF38058D</gtr:id><gtr:impact>Invited speaker at a Careers Day event, at St Anne's College, University of Oxford in April 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.cardiov.ox.ac.uk/rdm-careers-day-2</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit by Breast Cancer Now and the Sarah Greene Tribute Fund members and supporters: King's College London/Guy's Hospital laboratory site visit, 31st Jan 2017</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>06C38FC8-B73A-47BC-896E-0DD58770926A</gtr:id><gtr:impact>Our team co-hosted an afternoon visit by Breast Cancer Now and the Sarah Greene Tribute Fund members and supporters: King's College London/Guy's Hospital laboratory site visit, 31st Jan 2017. This event included presentations, question and answer sessions and visits to our laboratory facilities with presentations from laboratory group members.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical Trials Day held at Guy's Hospital in May 2015</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7777559E-4D20-4406-8C60-306B65F70EBC</gtr:id><gtr:impact>Our team provided stall cover and a poster on IgE antibodies in oncology for the Clinical Trials Day at Guy's Hospital.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Guy's and St Thomas's NHS Trust Members' Health Seminar, Dermatology, 7th September 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BD612D38-73F4-4D3E-8B98-13B630638EF0</gtr:id><gtr:impact>Invited to speak and engage with public at Guy's and St Thomas's NHS Trust Members' Health Seminar, Dermatology, 7th September 2016, Moles and Melanoma, Antibodies for cancer therapy; http://www.guysandstthomas.nhs.uk/news-and-events/past-events.aspx</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.guysandstthomas.nhs.uk/news-and-events/past-events.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory visit by patients and families from St John's Institute of Dermatology (skin cancer support group) on the 21st April 2016, St John's Institute of Dermatology, 9th floor, Guy's Tower Wing.</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>02CD6423-0336-4E96-9FA6-77A336B24BBF</gtr:id><gtr:impact>The Karagiannis group hosted an afternoon meeting and visit to the laboratories by patients and families from St John's Institute of Dermatology (skin cancer support group) on the 21st April 2016, St John's Institute of Dermatology, 9th floor, Guy's Tower Wing. Co-hosts: Consultant Dermatologist, Consultant Medical Oncologist, Clinical Psychologist, Skin Cancer, St John's Institute of Dermatology.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Nursing in Practice; Title: New tools to treat malignant melanoma.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9845BBCC-8011-492A-87B5-28C7332B404C</gtr:id><gtr:impact>Lead author of article in nursing magazine. 
Karagiannis SN*, Lacy KE. New tools to treat malignant melanoma. Nursing In Practice. http://www.nursinginpractice.com/article/new-tools-treat-malignant-melanoma, 20 May, 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.nursinginpractice.com/article/new-tools-treat-malignant-melanoma</gtr:url><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The South East London Cancer Consumer Panel for Research SELCRP</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>57BF6A48-6F99-49EB-9B73-96DA16726895</gtr:id><gtr:impact>I serve as a panel member (researcher expert/representative) supporting the panel's work providing research and ethics feedback to researchers.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.guysandstthomasbrc.nihr.ac.uk/PatientsPublic/Getinvolved/Haveyoursay/Cancer-research/Cancer-research.aspx</gtr:url><gtr:year>2013,2014,2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at Melanoma Discussion Group For Patients, Family &amp; Friends,  St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Trust</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DC91E10C-C2A5-4335-8BC0-25FA33BD6C12</gtr:id><gtr:impact>Invited to this patient support group to discuss research on melanoma and design of antibodies including those of the IgE class.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Academy of Allergy and Clinical Immunology (EAACI) Task Force Status Award</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>European Academy of Allergy and Clinical Immunology (EAACI)</gtr:fundingOrg><gtr:fundingRef>AllergoOncology Task Force, Award for Task Force Activities part of the European Academy of Allergy and Clinical Immunology (EAACI)</gtr:fundingRef><gtr:id>7E53CEF8-8D58-4DEE-BF3D-F4C208BC16D8</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR PhD studentship scheme</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>NIHR BRC Biomedical Research Centre</gtr:fundingOrg><gtr:id>7392BE9E-CA0B-4C96-B1F0-74AA30CF7900</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EAACI Exchange Research Fellowship</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>European Academy of Allergy and Clinical Immunology (EAACI)</gtr:fundingOrg><gtr:fundingRef>For Ms Judit Fazekas from the Medical University of Vienna, Project title: Cloning And Characterization Of Anti-HER-2 Immunoglobulins Of Different Ig-Classes In Regard Of ADCC And ADCP</gtr:fundingRef><gtr:id>068EAAEA-D616-48E6-9B91-F0458CA7E018</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258234</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Phase I study of MOv18, a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours: pre-clinical and clinical evaluations.</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>4AD6A1C2-CFCA-4A48-8882-39F718031C0F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2830</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Boehringer Ingelheim Fonds travel grant</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Boehringer Ingelheim Fonds</gtr:fundingOrg><gtr:fundingRef>Ms Judit Fazekas, Medical University of Vienna, travelling fellowship to King's College London</gtr:fundingRef><gtr:id>8A78346D-9C12-423A-912F-B1CDECB334B8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70794</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>5ED5C191-6346-40E5-A39A-28129399E916</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This clinical study relates to MOv18 IgE, a chimeric anti-folate receptor alpha (FRa) monoclonal IgE antibody. Extensive pre-clinical research studies have led to this first-in-human (FIH), first-in-class, proof-of-concept trial of MOv18 IgE, in patients with advanced cancer to investigate the potential of the IgE class of antibodies in solid tumour indications.</gtr:description><gtr:id>3EE0DEA2-2871-4AD2-906C-1B47B222389E</gtr:id><gtr:impact>This trial is first time a therapeutic antibody of the IgE class has been administered to man. The data generated from the trial will
provide essential information to aid the development of this particular agent and other future IgE therapeutics, including IgE analogues of existing therapeutic IgG monoclonal antibodies, as well as new agents.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MOv18 IgE: Phase I study of a first in class chimeric IgE antibody against folate receptor-a, in patients with advanced solid tumours</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02546921</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95B3FA37-682D-4710-8A2C-7248429B0A50"><gtr:id>95B3FA37-682D-4710-8A2C-7248429B0A50</gtr:id><gtr:title>IgG4 Characteristics and Functions in Cancer Immunity.</gtr:title><gtr:parentPublicationTitle>Current allergy and asthma reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97088b6667f0d3a3c5ac6a574fddd6a1"><gtr:id>97088b6667f0d3a3c5ac6a574fddd6a1</gtr:id><gtr:otherNames>Crescioli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6243B7C3-4A24-4C60-ADEF-D33C3FFE831D"><gtr:id>6243B7C3-4A24-4C60-ADEF-D33C3FFE831D</gtr:id><gtr:title>Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64b5af9189942a9600c7e57404549314"><gtr:id>64b5af9189942a9600c7e57404549314</gtr:id><gtr:otherNames>Wulaningsih W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC23E318-DD73-46E2-864A-4ADF46C6733D"><gtr:id>CC23E318-DD73-46E2-864A-4ADF46C6733D</gtr:id><gtr:title>Anti-Folate Receptor-a IgE but not IgG Recruits Macrophages to Attack Tumors via TNFa/MCP-1 Signaling.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85CCBD72-3D4E-458A-85D5-6EB0FCD75FAD"><gtr:id>85CCBD72-3D4E-458A-85D5-6EB0FCD75FAD</gtr:id><gtr:title>Beta-glucan contamination of pharmaceutical products: How much should we accept?</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ecee3102d6d0eea24f813f4ae1d3b415"><gtr:id>ecee3102d6d0eea24f813f4ae1d3b415</gtr:id><gtr:otherNames>Barton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9FC73242-0CD8-405E-A3B2-890E3128EEC2"><gtr:id>9FC73242-0CD8-405E-A3B2-890E3128EEC2</gtr:id><gtr:title>Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f5cf125bb61b8a825e1364b81e3ebd6"><gtr:id>3f5cf125bb61b8a825e1364b81e3ebd6</gtr:id><gtr:otherNames>Josephs DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2220009-3E3C-4FB5-B091-152440B95104"><gtr:id>B2220009-3E3C-4FB5-B091-152440B95104</gtr:id><gtr:title>IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f76e9f74d79333b9e957068eaf172892"><gtr:id>f76e9f74d79333b9e957068eaf172892</gtr:id><gtr:otherNames>Saul L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D25A21A2-8008-4958-B709-8DD6AE4AB342"><gtr:id>D25A21A2-8008-4958-B709-8DD6AE4AB342</gtr:id><gtr:title>TGF-?-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ecf3873733a85d146c7f044153f1893"><gtr:id>2ecf3873733a85d146c7f044153f1893</gtr:id><gtr:otherNames>Cantelli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A25B3BD3-9CCA-41AC-8BEF-7624D885D4CF"><gtr:id>A25B3BD3-9CCA-41AC-8BEF-7624D885D4CF</gtr:id><gtr:title>Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies.</gtr:title><gtr:parentPublicationTitle>Biotechnology progress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a4eec9191390666fc60045d7ccd605d"><gtr:id>6a4eec9191390666fc60045d7ccd605d</gtr:id><gtr:otherNames>Vigor K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1520-6033</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F328F95-29D0-4734-BF64-B96B17E4C543"><gtr:id>0F328F95-29D0-4734-BF64-B96B17E4C543</gtr:id><gtr:title>AllergoOncology - the impact of allergy in oncology: EAACI position paper.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97f8f42df40afcf8943e0fbac65d1b90"><gtr:id>97f8f42df40afcf8943e0fbac65d1b90</gtr:id><gtr:otherNames>Jensen-Jarolim E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0409D01F-781F-4710-BBCA-421C5B1BBA24"><gtr:id>0409D01F-781F-4710-BBCA-421C5B1BBA24</gtr:id><gtr:title>Therapeutic targets and new directions for antibodies developed for ovarian cancer.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b9b8f51329782767b6c073691d2c327"><gtr:id>4b9b8f51329782767b6c073691d2c327</gtr:id><gtr:otherNames>Bax HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99C21E49-C9B0-4BC9-A9F3-5D4479A24CB2"><gtr:id>99C21E49-C9B0-4BC9-A9F3-5D4479A24CB2</gtr:id><gtr:title>Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1ca9da6894e26b6337b69fcd4be667c"><gtr:id>c1ca9da6894e26b6337b69fcd4be667c</gtr:id><gtr:otherNames>Karagiannis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACCC8DD3-CB14-4F34-8513-7E0A73C23075"><gtr:id>ACCC8DD3-CB14-4F34-8513-7E0A73C23075</gtr:id><gtr:title>Targeting folate receptor alpha for cancer treatment.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7e79eb694a13631a2abaed50a822cc21"><gtr:id>7e79eb694a13631a2abaed50a822cc21</gtr:id><gtr:otherNames>Cheung A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L023091/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>